STAT+: A Supreme Court review of a contentious patent issue would change the way pharma claims discoveries
In the coming weeks, the Supreme Court is expected to decide whether to review a…
Category: STAT+
STAT+: George Church startup Manifold Bio raises $40M for ‘protein barcoding’ technology to improve drug testing
Manifold Bio, a new startup founded by one of Boston’s most prolific biotech entrepreneurs, has…
STAT+: Pharmalittle: Teva asks U.S. Supreme Court to review skinny labeling; European Commission rebuked for Pfizer texts
Top of the morning to you. And a steamy one, it is. In fact, there…
.jpg)
Opinion: STAT+: Value-based drug pricing: When does it work best?
Value-based drug pricing offers an important way to bring down the high cost of drugs…
STAT+: Nursing shortage at Mass. hospitals leads to multimillion-dollar costs
A widespread shortage of nurses at Massachusetts hospitals is only getting more extreme, with an…
STAT+: Pharmalittle: Covid worsened antibiotic resistance; Teva and AbbVie unit settle opioid suit with San Francisco
Hello, everyone, and how are you this fine, sunny morning? The middle of the week…
STAT+: Agios Pharma CEO Jackie Fouse to step down, as a former Alexion executive takes over
Jackie Fouse is stepping down as CEO of Agios Pharmaceuticals, replaced by Brian Goff, a…
STAT+: ‘Eye-opening’: The pandemic accelerated antimicrobial resistance across the U.S.
Resistance to medicines for combating superbugs has considerably worsened during the pandemic, with deaths and…
STAT+: Pharmalittle: N.Y. AG claims Teva lied about its role in the opioid crisis; doctors question compounded versions of Novo weight loss drug
Top of the morning to you, and a fine one it is. Clear blue skies…
STAT+: Verve Therapeutics begins human tests of first ‘base editor,’ aiming at heart disease
Somewhere in New Zealand, the first patient ever has been dosed with a kind of…
STAT+: Pharmalittle: Perrigo seeks FDA approval to sell birth control over the counter; 1.1 billion Covid vaccines have been wasted
Good morning, everyone, and nice to see you again after we disappeared for a needed…
STAT+: Pharmalittle: California to make its own low-cost insulin; Theranos jury finds Balwani guilty on all counts
Good morning, one and all. Damian Garde here, filling in for Ed Silverman once again…
Opinion: STAT+: How pharma and biotech can keep innovating in a bear market
Over the last decade, the biotech sector experienced the largest boom it has ever seen….
STAT+: Drug companies will have to start refunding Medicare for certain drugs that get thrown out
Starting next year, pharmaceutical companies will have to repay Medicare for any unused amount of drugs…
STAT+: Pharmalittle: Merck closes in on acquisition of Seagen; Intercept declares victory after re-analyzing NASH data
Good morning, everyone. Damian Garde here, filling in for Ed Silverman as the days of…
STAT+: With ‘do-over’ NASH results, Intercept will seek approval for first-ever treatment for fatty liver condition
Intercept Pharmaceuticals said Thursday that an extensive re-analysis of a large clinical trial involving its…
STAT+: In a high-profile misstep, the FDA backtracks on its ban on Juul
WASHINGTON — The FDA suddenly reversed course this week on its efforts to ban Juul…
STAT+: Here’s what Democrats changed in their latest drug pricing bill
WASHINGTON — Senate Democrats have put final tweaks on their drug pricing proposal, as they…
STAT+: In the search for an ARPA-H director, the White House is zeroing in on DARPA veterans
WASHINGTON — The White House is zeroing in on former DARPA officials as candidates to…
STAT+: Under new ownership, IBM Watson Health’s core assets get a rebranding
The IBM Watson Health brand comes with baggage. But for its new owners, the core…
STAT+: Pharmalittle: Some scientists want more Vertex CRISPR data; Biogen Alzheimer’s drug to get priority review
Good morning. Elizabeth Cooney here, sitting in for Ed Silverman again, wishing him sunny skies…
Opinion: STAT+: Why health care organizations need to invest in workforce career advancement
In a tight health care labor market, health care companies must be creative in attracting…
STAT+: Beyond a CRISPR treatment’s encouraging results, some scientists see a need for more data on risk
What happens when you CRISPR people? Few questions generated more contentious discussion in biotech in…
STAT+: FDA to convene second panel of outside experts to review Amylyx Pharma’s ALS treatment
Amylyx Pharmaceuticals said Tuesday that the Food and Drug Administration is bringing together a panel…
STAT+: Pharmalittle: Market downturn chills VC climate; drug distributors prevail in W. Va. opioids case
Good morning. Elizabeth Cooney here again, pinch-hitting for Ed Silverman. Although he sometimes makes his…
STAT+: Marijuana-induced high blunted by Anebulo Pharma pill, early study shows
Anebulo Pharmaceuticals said Tuesday that a single dose of its experimental pill blunted the effects…
STAT+: The Q3 health tech tracker: 11 key industry events and debates to watch
It’s been a humbling first half of the year for health tech companies. Previously abundant…
STAT+: The biotech scorecard for the third quarter: 18 stock-moving events to watch
Here is STAT’s biotech scorecard, our regular ledger of stock-moving biotech events, for the third…
STAT+: ‘Really scared and frightened’: VC deals and valuations begin falling apart as biotech’s stock shock becomes one of the longest in history
The drug industry is experiencing one of the longest market downturns it has ever seen,…
STAT+: Can Biogen’s backup plan for Alzheimer’s succeed?
Everyone needs a backup plan, including one of the biggest biotech companies in town. So…
STAT+: ‘A slippery slope’: Pfizer sells a contraceptive and donated to political groups that could come after the company
Generally speaking, a company would not want to contribute to a politician whose actions could…
STAT+: ‘A slippery slope’: Drugmakers that sell contraceptives donated to political groups that could come after them
Generally speaking, a company would not want to contribute to a politician whose actions could…
STAT+: Pharmalittle: Senate Dems vet a tweaked version of drug-pricing bill; biotechs double down on developing birth control products
And so, another working week will soon draw to a close. Not a moment too…
STAT+: Not-so-happy midyear! Biotech CEOS, best and worst, and a hopeful sign of a turnaround
A few things on my mind: A very strange — and painful — year in…
STAT+: After abortion ruling, biotechs developing contraceptives say their work is more important — and fraught — than ever
SAN DIEGO — From San Diego to New Jersey, biotechs developing new forms of birth…
STAT+: Medicare wants to stop publishing some hospital safety data next year
Ann MacDonald took painstaking effort to choose the very best surgeon for her mom’s colon…
STAT+: A Celldex treatment induces symptom relief in patients with chronic hives
An experimental drug from Celldex Therapeutics induced complete symptom relief in half of patients with…
STAT+: The near-term outlook for pharma industry earnings just got a little worse
The near-term earnings outlook for the pharmaceutical industry was revised downward by a major credit…
STAT+: New analysis of Amarin’s Vascepa resurrects big questions about effectiveness
A new analysis of Vascepa, a medicine derived from fish oil and used to prevent…
STAT+: Pharmalittle: Pfizer and U.S. strike $3.2 billion deal for Covid vaccine; marketing of morning-after pills shifts to mail-order options
Good morning, everyone, and nice to see you again after we took an all-too-quick, day-long…
STAT+: A rich Republican businessman is an unlikely champion for lower hospital prices — but he’s winning the fight
INDIANAPOLIS — Al Hubbard isn’t the typical crusader for lowering health care costs. Hubbard and…
STAT+: Pharmalittle: FDA panel urges revamped Covid boosters; White House to widen access to monkeypox vaccine
Good morning. Elizabeth Cooney here, sitting in for Ed Silverman as he takes a day…
STAT+: ARCH Venture Partners raises $3 billion fund to invest in biotech startups despite brutal stock downturn
The market for biotechnology stocks is ghastly, but ARCH Venture Partners, one of the largest…
STAT+: 100 lawmakers ask HHS to use controversial federal laws to combat high drug prices
A group of 100 federal lawmakers is urging the Biden administration to use controversial provisions…
STAT+: Pharmalittle: Retailers ration contraceptive pills as demand spikes; Supreme Court rules doctors must knowingly misprescribe opioids to be convicted
Top of the morning to you, and a fine one it is. Clear blue skies…
STAT+: What we know — and what we may never know — about why the FDA banned Juul
WASHINGTON – Even some of the nation’s top tobacco experts were surprised by the Food…
.jpg)
STAT+: Cognito Therapeutics raises $50 million for Alzheimer’s treatment tech
Cognito Therapeutics has raised $50 million in funding as it seeks to advance treatments for…
STAT+: Pharma largely failed to follow human rights principles with its Covid-19 vaccines and drugs
More than two years after the Covid-19 pandemic emerged, a new scorecard finds that 19…
STAT+: Pharmalittle: Abortion pills will be at center of legal battles; Gilead reaches $33 million settlement over patient assistance programs
Good morning, everyone, and welcome to another working week. We hope the weekend respite was…
STAT+: A ‘colossal financial fraud’: Gilead to get $33 million from a clinic for exploiting its HIV patient assistance program
After nearly two years of courtroom squabbling, Gilead Sciences reached a $33 million settlement with…